Skip to content
soligenix-logo
Soligenix Logo
Main Menu
About Soligenix
Show submenu
Corporate Overview
Board of Directors
Executive Team
Scientific Advisory Boards
Show submenu
Scientific Advisory Board Cutaneous T-Cell Lymphoma
European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Scientific Advisory Board Oral Mucositis
Scientific Advisory Board Pediatric Crohn’s Disease
Behçet’s Disease Medical Advisory Board
Scientific Advisory Board Antibiotic Resistance & Emerging Infectious Disease
Scientific Advisory Board Psoriasis
Careers
Show submenu
Job Openings
Contact
Search Site
Search
Search Press Releases
Search
Pipeline + Programs
Show submenu
Pipeline
Specialized BioTherapeutics
Show submenu
HyBryte™ Cutaneous T-Cell Lymphoma (CTCL) Treatment
SGX302 Plaque Psoriasis Treatment for Mild to Moderate Psoriasis
SGX942 for Oral Mucositis Treatment
SGX945 for Aphthous Ulcers of Behçet’s Disease
SGX203 for Pediatric Crohn’s Disease
Public Health Solutions
Show submenu
RiVax® to Prevent Ricin Poisoning
SGX943 for Bacterial Infection Treatment
ThermoVax® Thermostable Vaccines for Global Use
Reference Literature
Show submenu
Specialized BioTherapeutics
Public Health Solutions
Relevant Publications
Clinical Trials
Our Focus
Show submenu
Specialized BioTherapeutics
Show submenu
Cutaneous T-Cell Lymphoma
Psoriasis
Oral Mucositis
Behçet’s Disease
Pediatric Crohn’s Disease
Public Health Solutions
Show submenu
What is Ricin Intoxication?
Thermal Stabilization of Vaccines
Antibiotic Resistant & Emerging Infectious Disease
Partnering
Investors
FCOI Disclosures
Currently, Soligenix, Inc. does not have any required FCOI Disclosures.